Vinpocetin-BP

Vinpocetinum

1 ml of concentrate for solution for infusion contains vinpocetine 5 mg; each 2 ml ampoule contains vinpocetine 10 mg, and each 5 ml ampoule contains vinpocetine 25 mg. Excipients with known effect: sodium metabisulfite, benzyl alcohol and sorbitol (2.00 mg / 20.00 mg / 160.00 mg per 2 ml ampoule; 5.00 mg / 50.00 mg / 400.00 mg per 5 ml ampoule).

Indication: Neurology: treatment of various forms of cerebral circulatory disorders (transient ischaemic attack, post-stroke states, vascular dementia, cerebral arteriosclerosis, post-traumatic or hypertensive encephalopathy, vertebrobasilar insufficiency). Ophthalmology: chronic vascular disorders of the choroid and retina. ENT: perceptive presbyacusis, Ménière's disease and tinnitus.

Contraindications (SmPC sec. 4.3): 4.3 Contraindications − hypersensitivity to the active substance or to any of the excipients listed in section 6.1. − acute phase of cerebral haemorrhage − severe coronary ischaemia − presence of severe cardiac arrhythmias − pregnancy, breast-feeding, and use in women of childbearing potential not using a reliable contraceptive method. Vinpocetine-BP concentrate for solution for infusion is contraindicated in children (due to lack of clinical data).

Special warnings and precautions (SmPC sec. 4.4, excerpt): 4.4 Special warnings and precautions for use Vinpocetine-BP concentrate for solution for infusion should be administered only after evaluation of the risk/benefit ratio in patients with increased intracranial pressure, in patients receiving antiarrhythmic agents, and in patients with arrhythmias and long QT syndrome. ECG monitoring is recommended in cases of long QT syndrome or during concomitant treatment with medicinal products that prolong the QT interval. Excipients This medicinal product contains 80 mg sorbitol per mL. Sorbitol is a source of fructose. The additive effect of concomitantly administered products containing sorbitol (or fructose) and dietary intake of sorbitol (or fructose) should be taken into account. Patients with hereditary fructose intolerance (HFI) should not be given this medicinal product unless strictly necessary. A history […]